In terms of other mutations analyzed, the presence of TP53 mutations has been associated with a poor prognosis for patients diagnosed with lymphoid malignancies, including those with newly diagnosed GCB DLBCL treated with R-CHOP [9]. This evidence concerns the gene TP53 and diffuse large B-cell lymphoma.